We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+34.56%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.99M
AUM Growth
-$1.3B
(-100%)
Cap. Flow
-$1.31B
Cap. Flow
% of AUM
-65,665.63%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
43
New
–
Increased
–
Reduced
2
Closed
41
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$175M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$115M |
| 3 |
IMGO
Imago BioSciences, Inc. Common stock
IMGO
|
+$70.4M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$60.7M |
| 5 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
+$60M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRRA
1
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.75M | 88.13% |
54,654
-1,210,207
| -96% | -$34.7M |
|
|
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
| $236K | 11.87% |
1,019,288
-632,069
| -38% | -$262K |
|
3
Aclaris Therapeutics
ACRS
$908M
| – | – |
-408,329
| Closed | -$5.94M |
|
4
AnaptysBio
ANAB
$1.71B
| – | – |
-899,700
| Closed | -$31.3M |
|
|
5
Arcutis Biotherapeutics
ARQT
$3.14B
| – | – |
-8,434,232
| Closed | -$175M |
|
6
Arvinas
ARVN
$607M
| – | – |
-163,763
| Closed | -$13.5M |
|
|
AUTL
7
Autolus Therapeutics
AUTL
$625M
| – | – |
-3,746,857
| Closed | -$19.4M |
|
|
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-951,814
| Closed | -$7.69M |
|
|
BCYC
9
Bicycle Therapeutics
BCYC
$303M
| – | – |
-555,240
| Closed | -$33.8M |
|
10
Cogent Biosciences
COGT
$6.45B
| – | – |
-1,774,891
| Closed | -$15.2M |
|
11
Crinetics Pharmaceuticals
CRNX
$9B
| – | – |
-1,384,293
| Closed | -$39.3M |
|
|
EPIX
12
DELISTED
ESSA Pharma
EPIX
| – | – |
-543,470
| Closed | -$7.72M |
|
13
Immunovant
IMVT
$9.05B
| – | – |
-585,759
| Closed | -$4.99M |
|
14
Iovance Biotherapeutics
IOVA
$3.76B
| – | – |
-1,747,622
| Closed | -$33.4M |
|
|
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,305,087
| Closed | -$17.3M |
|
16
Krystal Biotech
KRYS
$10.6B
| – | – |
-771,250
| Closed | -$53.9M |
|
17
Mirum Pharmaceuticals
MIRM
$6.09B
| – | – |
-3,566,912
| Closed | -$56.9M |
|
|
MRUS
18
DELISTED
Merus
MRUS
| – | – |
-559,179
| Closed | -$17.8M |
|
19
Passage Bio
PASG
$14.4M
| – | – |
-250,461
| Closed | -$31.8M |
|
20
Vaxcyte
PCVX
$9.13B
| – | – |
-2,309,554
| Closed | -$54.9M |
|
|
21
Phathom Pharmaceuticals
PHAT
$723M
| – | – |
-5,827,415
| Closed | -$115M |
|
22
Replimune Group
REPL
$1.48B
| – | – |
-650,862
| Closed | -$17.6M |
|
23
Regenxbio
RGNX
$619M
| – | – |
-235,809
| Closed | -$7.71M |
|
|
SLN
24
Silence Therapeutics
SLN
$835M
| – | – |
-886,173
| Closed | -$21.2M |
|
|
25
Syndax Pharmaceuticals
SNDX
$1.8B
| – | – |
-2,772,062
| Closed | -$60.7M |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q1 2022 Portfolio in Review
As of Q1 2022, Frazier Management held 43 positions worth $1.99M, down 100% from $1.3B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Frazier Management withdrew a net $1.31B in Q1 2022, closing 41 positions and reducing 2 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $175M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
- Frazier Management's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $34.7M.
- Frazier Management fully exited Arcutis Biotherapeutics in Q1 2022, selling an estimated $175M.
- Frazier Management's ten largest holdings make up 100% of its $1.99M portfolio in Q1 2022.
- Frazier Management opened 0 new positions and closed 41 in Q1 2022.
- Frazier Management's portfolio value fell 100% quarter-over-quarter to $1.99M.
Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.